Fat-free mass change after nutritional rehabilitation in weight losing COPD: role of insulin, C-reactive protein and tissue hypoxia by Baldi, Simonetta et al.
© 2010 Baldi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of COPD
International Journal of COPD 2010:5 29–39 29
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
O R I g I n A L   R e s e A R C h
Fat-free mass change after nutritional 
rehabilitation in weight losing COPD: role 
of insulin, C-reactive protein and tissue hypoxia
simonetta Baldi 
Roberto Aquilani 
gian Domenico Pinna 
Paolo Poggi 
Angelo De Martini 
Claudio Bruschi
Department of Pneumology and 
Biomedical engineering, scientific 
Institute of Montescano, salvatore 
Maugeri Foundation I.R.C.C.s. 
Pavia, Italy
Correspondence: simonetta Baldi 
U.O. di Riabilitazione specialistica –  
Pneumologia Riabilitativa, Istituto 
Scientifico di Montescano,  
Fondazione s Maugeri, IRCCs, Via Per 
Montescano no. 31, 27040 Montescano 
(Pavia) Italy 
Tel +39 0385 247227 
Fax +39 0385 61386 
email simonetta.baldi@fsm.it
Background: Fat-free mass (FFM) depletion marks the imbalance between tissue protein 
synthesis and breakdown in chronic obstructive pulmonary disease (COPD). To date, the role of 
essential amino acid supplementation (EAAs) in FFM repletion has not been fully acknowledged. 
A pilot study was undertaken in patients attending pulmonary rehabilitation.
Methods: 28 COPD patients with dynamic weight loss  5% over the last 6 months were ran-
domized to receive EAAs embedded in a 12-week rehabilitation program (EAAs group n = 14), 
or to the same program without supplementation (C group n = 14). Primary outcome measures 
were changes in body weight and FFM, using dual X-ray absorptiometry (DEXA).
Results: At the 12th week, a body weight increment occurred in 92% and 15% of patients in 
the EAAs and C group, respectively, with an average increase of 3.8 ± 2.6 kg (P = 0.0002) 
and −0.1 ± 1.1 kg (P = 0.81), respectively. A FFM increment occurred in 69% and 15% of EAAs 
and C patients, respectively, with an average increase of 1.5 ± 2.6 kg (P = 0.05) and −0.1 ± 2.3 kg 
(P = 0.94), respectively. In the EAAs group, FFM change was significantly related to fasting 
insulin (r2 0.68, P  0.0005), C-reactive protein (C-RP) (r2 = 0.46, P  0.01), and oxygen 
extraction tension (PaO2x) (r2 = 0.46, P  0.01) at end of treatment. These three variables were 
highly correlated in both groups (r  0.7, P  0.005 in all tests).
Conclusions: Changes in FFM promoted by EAAs are related to cellular energy and tissue 
oxygen availability in depleted COPD. Insulin, C-RP, and PaO2x must be regarded as clinical 
markers of an amino acid-stimulated signaling to FFM accretion.
Keywords: COPD, pulmonary rehabilitation, branched chain amino acids, insulin, systemic 
inflammation
Introduction
Cachexia, defined as weight loss with disproportional fat-free mass wasting, occurs in 
about one-third of patients with severe chronic obstructive pulmonary disease (COPD) 
eligible for pulmonary rehabilitation,1 and represents a cause of increased mortality 
independent of ventilatory limitation.2
Despite the fact that fat-free mass (FFM) depletion is recognized as a marker 
of the imbalance between tissue protein synthesis and breakdown in chronic wast-
ing syndrome, there is insufficient knowledge about the determinants of the switch 
to catabolic intermediary metabolism during the course of the disease. Previous 
studies have documented a fall in muscle protein synthesis in depleted patients with 
emphysema,3 and a high protein turnover in post-absorptive state in stable COPD 
patients.4 Further studies5–8 have also indicated that an elevated inflammatory state 
has consequences for protein need and intermediary metabolism, putting forward the International Journal of COPD 2010:5 30
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idea that a hypoxic-mediated and cytokine-mediated wasting 
occurs in COPD patients, who involuntary lose weight.
These findings would entail making accretion or 
maintenance of FFM a rehabilitation strategy to amplify 
reconditioning effects of physical training and to improve 
physical performance in depleted COPD patients. As similar 
strategies are not fully acknowledged yet, future studies 
capable of either addressing the issue of prevention of 
pulmonary cachexia, or shedding light on its pathogenesis 
are advisable. Metabolic studies9 have documented that high 
physiologic concentrations of branched chain amino acids, 
particularly leucine, exert a bi-directional modulation on 
insulin signaling pathways that promote protein synthesis 
and gluconeogenesis, while impairing glucose transport 
and glycogen synthesis. To date the idea of a cross-talk 
between amino acid and insulin signaling to glucose and 
protein metabolism remains largely speculative in depleted 
COPD patients. Thus, the present study has two aims. First, 
to evaluate the change in body weight and FFM after an 
essential amino acid supplementation (EAAs) intervention 
embedded in a rehabilitation program in weight-losing COPD 
patients. Second, to explore the mechanisms that modulate 
FFM accretion in response to ingestion of amino acids 
(ie, the factors that control protein turnover in tissues). We 
hypothesized a relationship between the supposed anabolic 
response to EAAs, ie, the change in FFM, and fasting insulin 
plasma levels, C-reactive protein (C-RP), and tissue oxygen 
availability assessed by oxygen extraction tension (PaO2x). 
The latter is a noninvasive measurement, which summarizes 
the degree of compensation among arterial oxygen tension, 
blood oxygen carrying capacity and affinity.10 In addi-
tion, the mutual interrelationships between insulin plasma 
levels, C-RP and PaO2x were investigated before and after 
12 weeks of nutrition and/or rehabilitation interventions.
Methods
Participants
Twenty-eight patients with severe COPD according to 
American Thoracic Society (ATS) criteria,11 and experi-
encing a dynamic weight loss (5% of body weight) over 
the previous 6 months were consecutively recruited at 
the start of an inpatient pulmonary rehabilitation program 
while clinically stable at the Pulmonary Rehabilitation Unit 
of S Maugeri Foundation I.R.C.C.S (Montescano-Italy). 
Exclusion criteria included: any malignancy, gastrointestinal 
disorders, severe endocrine disorders or recent surgery, recent 
(ie, within the last 4 weeks) respiratory tract infection, and 
abnormal fluid balance as manifested by the presence of edema 
or regular use of diuretics. The medical ethics committee of 
the Scientific Institute of Montescano approved the study 
design and a written informed consent was obtained prior 
to the study.
Pulmonary rehabilitation
All the eligible patients were randomly allocated to one 
of the following interventions: A) EAAs embedded in a 
4-week inpatient rehabilitation program, followed by EAAs 
embedded in an 8-week outpatient rehabilitation program 
(2 sessions a day of 30 minutes unloaded bicycle training) 
(EAAs group), and B) a 4-week inpatient rehabilitation 
program, followed by an 8-week outpatient rehabilitation 
program (2 sessions a day of 30 minutes unloaded bicycle 
training) (C group). All measurements were performed 
during the first 5 days after admission to the hospital and in 
addition after 12 ± 2 weeks of intervention. The response to 
nutrition and/or rehabilitation interventions was evaluated 
as body weight change, and FFM change reached at the 
end of nutritional rehabilitation. The essential and nones-
sential amino acid mixture (Aminotrofic®, Erre Kappa 
Euroterapici, Milan, Italy) contains high and balanced 
branched chain amino acid concentrations (see Table 1). The 
dosage was 4 g, given twice a day, as two liquid supplements 
of 200 mL each. The total protein content of the supple-
ment together with that of the consumed regular meals was 
more than enough to ensure the amount of protein needed 
for the optimal protein synthesis that is recommended for 
repletion of malnourished subjects (1.5 to 1.7 g protein/kg 
body weight/day).
Resting energy expenditure (REE) and dietary intake 
were assessed at baseline and end of treatment. REE was 
measured by an open circuit indirect calorimetry system using 
Table 1 essential amino acid composition
L-Leucine 1250 mg
L-Lysine 650 mg
L-Isoleucine 625 mg
L-Valine 625 mg
L-Threonine 350 mg
L-Cysteine 150 mg
L-histidine 150 mg
L-Phenylalanine 100 mg
L-Methionine 50 mg
L-Tyrosine 30 mg
L-Tryptophan 20 mg
B6 vitamin 0.15 mg
B1 vitamin 0.15 mgInternational Journal of COPD 2010:5 31
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a ventilated hood. Measurements were started in the early 
morning (08:00 hours). After an overnight fasting, patients 
had a period of at least 30 minutes of bed rest prior to the 
measurements during which subjects were comfortably lying 
on a bed in a supine position. After stabilization, REE was 
recorded during a period of 30 minutes and calculated from 
oxygen consumption and carbon dioxide production using 
the abbreviated Weir formula:
REE (kcal/h) = (3.9 × VO2 + 1.1 × VCO2) × 1.44/24.
Dietary intake was assessed using a 3-day food diary, by 
recording everything the patients ate or drank for 3 consecu-
tive days, using household measurements to quantify items. 
Physical activity performed which lasted 10 minutes was 
also recorded. Apparent discrepancies were checked with the 
subject. The information was coded for computer nutrient 
analysis by the same trained dietician. The nutrient data-
base was derived from the IEO food composition database 
(BDA).12 At end of treatment, a dietician reviewed the food 
diary to ascertain maintenance of actual content and total 
caloric value.
The inpatient rehabilitation program consisted of general 
physical training, with particular attention to exercise in 
relation to daily activities.13 Five days a week a combined 
endurance and strength exercise training was followed, 
consisting of 30 minutes of submaximal cycle ergometry, 
and 30 minutes of treadmill walking, and one session of 
unsupported arm exercise training. The submaximal cycle 
ergometry was set at 50% of peak workload and increased 
during the training progression under the supervision of an 
exercise therapist. The outpatient program was a 5-day week, 
self-reported home program.
Body composition
Body height and weight were measured to calculate body 
mass index. Possible disturbances in body composition were 
assessed by dual-energy X-ray absorptiometry (DEXA), 
which is a direct method of assessing bone mineral content 
and the soft tissue surrounding the bone: FFM and fat mass 
(FM). Each patient lying in supine position on a scan table 
for approximately 15 minutes was scanned by DPX-L Bone 
Densitometry (Lunar Radiation Corp., Madison, WI, USA). 
Total and subregional FM and FFM were derived accord-
ing to the computer algorithm (Lunar software version 1.3; 
Madison, WI, USA) provided by the manufacturer. The FFM 
index (FFMI) was calculated as FFM to height-squared ratio. 
According to previous studies14 a low FFMI was classified as 
a FFMI  15 kg/m2 (women) and  16 kg/m2 (men).
Lung function, and performance status
Lung function testing included spirometry FEV1 and 
FVC, thoracic gas volumes, and carbon monoxide (CO) 
transfer factor (TLCO), (Masterlab; Jaeger, Wurzurg, 
Germany). Predicted equations utilized were those of 
Quanjer et al.15 Arterial blood samples were gently drawn 
from the brachial artery using a dedicated pre-heparinized 
blood sampler, while patients were seated and breathing 
room air. Oxygen breathing was temporarily withdrawn 
for at least 30 minutes in patients under oxygen therapy. 
Immediately after sample collection, mixing, and removal 
of the first drops of blood, the acid-base and oxygen status 
were analyzed. Arterial negative logarithm of hydrogen ion 
concentration (pH) and arterial carbon dioxide tensions 
(PaCO2), together with arterial oxygen tension (PaO2) 
and the oximetry parameters were measured using a 
blood gas analyzer (ABL Model 700 System Radiometer, 
Copenhagen, Denmark). The following oximetry param-
eters were directly measured: 1) concentration of total 
hemoglobin in the blood (tHb), which includes all types 
of hemoglobin ie, oxy- (O2Hb), deoxy- (HHb), carboxy- 
(COHb), and meta-hemoglobin (MetHb); 2) arterial oxygen 
saturation (sO2) (ie, the ratio between the concentration 
of O2Hb and HHb + O2Hb); 3) fraction of oxyhemoglobin 
(FO2Hb) (ie, the ratio between the concentration of O2Hb 
and tHb); 4) fraction of carboxyhemoglobin (FCOHb) 
(ie, the ratio between concentration of COHb and tHb); 
5) fraction of metahemoglobin (FMetHb) (ie, the ratio 
between concentration of MetHb and tHb); 6) total arte-
rial oxygen content (ctO2) (ie, the sum of the concentra-
tion of hemoglobin-bound oxygen and the concentration 
of physically dissolved oxygen). The concentration of 
effective hemoglobin (ceHb), ie, the concentration of total 
hemoglobin (ctHb) corrected for fractions of carboxyhe-
moglobin (FCOHb) and metahemoglobin (FMetHb), which 
are unable to bind oxygen reversibly, was calculated as a 
measurement of hemoglobin oxygen binding capacity. Both 
oxygen tension at half saturation (50%) of blood (P50), 
and oxygen extraction tension of arterial blood (PaO2x), 
were calculated by extrapolation along the shape of the 
oxygen binding curve on the log PaO2-ctO2 diagram, by 
a dedicated computer program.16 The shape of the curve 
was modeled on the basis of the PaO2 and the hemoglobin 
oxygen saturation fraction measured in the arterial blood, 
using a hyperbolic tangent function.10 Performance status 
of the patients was assessed by body-mass index (B), the 
degree of airflow obstruction (O) and dyspnea (D), and 
exercise capacity (E) (BODE index).17International Journal of COPD 2010:5 32
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Blood sampling
Fasting blood samples were collected, early in the morning 
(08:00 to 10:00 hours). Plasma glucose concentration was 
determined by glucose oxidative methods (Dimension 
clinical chemistry system, Dade Behring), using a glucose 
auto analyzer. Plasma insulin (95% intra-assay coefficient of 
variation  29.1 µUI/mL) was determined by commercial 
radio-immuno assay (Immulite 2000, Siemens). C-reactive 
protein (CRP) was measured in duplicate by high sensitivity 
turbidimetric immuno-assay (PETIA) (Dade Behring), with 
a lower detection limit of 0.5 mg/L.
statistical analysis
Comparisons between groups were carried out by one-
factor ANOVA or Chi-square test if the examined variable 
was, respectively, continuous or categorical. To test for the 
effect of EAA supplementation on body weight and FFM, 
we used a two-factor ANOVA (factors: treatment and time, 
with repeated measurements in the latter), adjusting for sex. 
Univariable and multivariable linear regression analysis was 
used to assess the association between insulin, C-RP blood 
level and PaO2x, (the explanatory variables) and the change 
in FFM after nutritional intervention (the response variable). 
Multivariable model building was carried out by a forward 
selection procedure with 0.50 significance level for entry 
of variables into the model (Proc. Reg, SAS/STAT–SAS 
Institute Inc., Cary, NC, USA). Person’s correlation coef-
ficient was used to assess the association between continu-
ous variables. All tests were two-tailed and a P  0.05 was 
considered statistically significant. Descriptive statistics are 
given as mean (±SD) or as a percentage value for continuous, 
and respectively categorical variables.
Results
Figure 1 details the flow diagram for patients’ allocation to 
the intervention groups.
The majority of patients (96%) were on maintenance 
medication consisting of inhaled β2-agonists, and inhaled 
corticosteroids therapy; none of them took systemic steroids 
at the time of the study.
Baseline anthropometrics, smoking habitus, performance 
status and lung function data in the EAAs and C groups 
are reported in Table 2. The two groups were comparable 
for age, smoking habit and performance status as assessed 
Assessed for eligibility
No. 32
Refused to participate
No. 4
§ §
No. 14 to Rehab No. 14 to EAAs + Rehab
Lost to follow-up No. 1
Low home adherence No. 2
Lost to follow-up No. 1
Low home adherence No. 2
Analyzed No. 13 Analyzed No. 13
Allocated to interventions
No. 28
Figure 1 The flow diagram for patients’ allocation to EAAs + rehabilitation and rehabilitation interventions.
§number of patients who did not exercise on a regular basis and/or spontaneously reduced the dose of eAA to 4 g daily.
Abbreviation: eAAs, essential amino acid supplementation.International Journal of COPD 2010:5 33
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by the four domains of the BODE index, and pulmonary 
functional impairment. A higher number of females were 
allocated to the C group. The frequency of patients with 
long term oxygen therapy was evenly distributed between 
the groups.
Table 3 reports baseline body composition, dietary intake, 
resting energy expenditure, oxygen status of arterial blood, 
and laboratory parameters in both groups. All these variables 
were comparable in the two groups. In both groups weight 
loss in the previous 6 months occurred due to hypermetabo-
lism, despite a normal baseline dietary intake, and resulted in 
FFM depletion in 77% of patients. The average C-RP mg/L 
was increased over normal values, while insulin and glucose 
plasma levels measured in the fasting state were within the 
normal range in all the patients. In addition, the serum con-
centrations of creatinine within the normal range indicated 
a normal kidney function in all the patients.
At the 12th week, the change in dietary intake was 34 ± 
92 kcal/24 h in the EAAs group, and 43 ± 87 kcal/24 h in 
the C group (P = 0.80); change in resting energy expendi-
ture as a percentage of Harris-Benedict prediction equation, 
was −19% ± 17% in the EAAs group, and –12% ± 15% in 
the C group (P = 0.28). The change in insulin, C-RP and 
PaO2x was, respectively, –0.9 ± 4.4 µUI/mL (P = 0.49), 
0.2 ± 3.7 mg/L (P = 0.83) and −0.3 ± 2.7 mmHg (0.73) 
in the EAAs group. In the C groups these changes were, 
respectively, −0.6 ± 2.1 µUI/mL (P = 0.33), 1.0 ± 8.7 mg/L 
(P = 0.71) and 0.9 ± 2.7 mmHg (P = 0.26). The change in 
glucose blood level was −0.7 ± 12.7 mmol/L (P = 0.85) and 
4.1 ± 16.4 mmol/L (P = 0.39) in the EAAs and C group, 
respectively.
A body weight increment occurred in 12 out of 13 patients 
(92%) in the EAAs group, and in 2 out of 13 (15%) in the 
C group. Body weight increased by 3.8 ± 2.6 kg in the 
EAAs group (P = 0.0002) and −0.1 ± 1.1 kg in the C group 
(P = 0.81). The interaction test between the treatment and 
time factors (P = 0.0001) further supported the significance of 
the different response in the two groups. An FFM increment 
occurred in 9 out of 13 patients (69%) in the EAAs group, 
and in 2 out of 13 (15%) in the C group. FFM increased by 
1.5 ± 2.6 kg in the EAAs group (P = 0.05) and −0.1 ± 2.3 kg 
in the C group (P = 0.94). The interaction test between 
the treatment and time factors was borderline significant 
(P = 0.05).
In order to explore the mechanisms that modulate FFM 
accretion in response to ingestion of amino acids, we assessed 
the association between the change in FFM and 12th-week 
insulin plasma level, C-RP, and PaO2x, in the EAAs group. 
Table 2 Baseline characteristics of the 28 weight-losing patients with COPD: anthropometrics, smoking habitus, oxygen therapy, 
performance status and lung function data
Characteristics   EAAs group C group P value
started/Completed no 14/13 14/13
Age years 73.1 (6.0) 70.1 (5.8) 0.29
gender M/F 12 2 8 6 †0.09
smokers Current/ex 10 4 9 5 †0.32
Pack-years no 71.9 (28.5) 47.4 (29.8) 0.12
LTOT Y/n 3 11 3 11 0.25
BMI kg/m2 19.9 (2.8) 21.0 (3.8) 0.35
FeV1 % pred. 41.3 (14.1) 43.6 (14.42) 0.89
MMRC-D points 3.2 (0.8) 3.1 (0.7) 0.69
6MWD m 224.4 (153.9) 259.5 (120.5) 0.51
BODe points 6.6 (2.4) 6.2 (1.9) 0.82
VC % pred 70.7 (13.2) 79.7 (8.7) 0.09
FeV1/VC % 40.2 (14.1) 47.3 (13.8) 0.89
TLC % pred 119 (10.8) 110.8 (23.4) 0.70
RV % pred 165.4 (29.3) 178.4 (60.1) 0.35
TLCO % pred 40.5 (14.1) 43.3 (16.9) 0.63
Note: Baseline statistics are given as means and (sD). †by χ2 test.
Abbreviations: BMI, body mass, index; BODE, degree of airflow obstruction, dyspnea and exercise capacity index; COPD, chronic obstructive pulmonary disease; Pack-years, 
no. cigarettes/day/20 years of smoking; LTOT, long-term oxygen therapy; FeV1, forced expiratory volume in one second; MMRC-D, scores on the Modified Medical Research 
Council dyspnea scale; 6MWD, distance walked in 6 minutes;   VC, slow vital capacity; FeV1/VC,   Tiffeneau index;  TLC, total lung capacity; RV residual volume;   TLCO, CO transfer 
factor.International Journal of COPD 2010:5 34
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Univariable linear regression results are shown in Figure 2. 
To investigate a possible direct effect of glucose blood level on 
FFM change, we also included in this figure a plot showing the 
relationship between change in FFM and 12th-week glucose 
level. A substantial linear association was found between 
the change in FFM and insulin plasma levels (r2 = 0.68, 
P  0.001 – Figure 2, panel A), while a moderate associa-
tion was found between the change in FFM and both C-RP 
(r2 = 0.46, P  0.01 – Figure 2, panel B) and PaO2x (r2 = −0.46, 
P  0.01 – Figure 2, panel C). On the contrary, there was no 
association change in FFM and fasting glucose plasma levels 
(r2 = 0.04, P = 0.50 – Figure 2, panel D). As expected, insulin, 
C-RP, and PaO2x at the 12th week were mutually highly 
correlated (r  0.7, P  0.005 in all tests) (see Table 4).
The multivariable linear regression model included 
insulin and C-RP, with p values 0.019 and 0.45, respectively. 
This model explained 70% of the variance of the change 
in FFM after the rehabilitation program with amino acid 
supplementation. These results suggest that the predictive 
information of C-RP is already “contained” in that of the 
insulin variable, and that PaO2x does not provide any addi-
tive information to this two-variable model.
In the C group there was no significant association between 
change in FFM and 12th week insulin (r2: 0.0003, P = 0.95 –   
Figure 3, panel A), C-RP (r2: 0.10, P = 0.39 – Figure 3, 
panel B), and PaO2x (r2: 0.06, P = 0.42 – Figure 3, panel C). 
Furthermore, no association was found between change in 
FFM and fasting glucose plasma levels (r2 = 0.004, P = 0.98 –   
Figure 3, panel D). As found in the EAAs group, insulin, 
C-RP and PaO2x at the 12th week were mutually highly cor-
related (r  0.77, P  0.005 in all tests), (see Table 4).
Discussion
Results of this study suggest the potential for EAAs associ-
ated with physical training to halt or even reverse lean body 
mass depletion in hypoxemic COPD patients, who experience 
dynamic weight loss. Furthermore, the study provides several 
novel insights on the pathophysiological mechanisms that 
modulate FFM accretion in this disease condition.
First, the positive association between 12th-week FFM 
change and insulin plasma levels suggests a specific modula-
tion of insulin actions by the amino acid mixture on signal-
ing to protein metabolism in weight losing COPD patients. 
Second, the significant association between FFM change 
Table 3 Baseline characteristics in 28 weight-losing patients with COPD: body composition, dietary intake, resting energy expenditure, 
oxygen status, and laboratory parameters*
Characteristics   EAAS group  C group P value
started/Completed no 14/13 14/13
Body weight kg 55.7 (8.4) 57.8 (9.0) 0.59
FFM kg 42.7 (6.1) 39.5 (4.8) 0.24
FM kg 11.8 (6.6) 14.8 (6.1) 0.36
FFMI kg/m2 15.1 (2.0) 15.3 (2.0) 0.89
Dietary intake kcal/24 h 1897 (406) 1816 (308) 0.57
Ree kcal/24 h 1319 (305) 1282 (229) 0.73
Ree_hB % pred 146 (23) 137 (15) 0.25
PaCO2 mmhg 41.5 (6.9) 42.4 (6.7) 0.56
PaO2 mmhg 61.5 (9.8) 58.3 (6.8) 0.46
P50 mmhg 24.4 (4.2) 23.6 (1.9) 0.60
PaO2x mmhg 31.0 (2.7) 30.2 (2.4) 0.44
thb g/dL 13.7 (1.9) 14.2 (2.2) 0.86
Fasting glucose mmol/L 5.0 (0.6) 4.9 (0.7) 0.83
Fasting insulin µUI/ml 5.5 (4.7) 5.2 (4.8) 0.89
Albumin g/dL 3.4 (0.7) 3.5 (0.5) 0.62
Pre-albumin mg/dL 21.9 (5.6) 26.6 (6.2) 0.09
Creatinine mg/dL 0.9 (0.2) 0.9 (0.1) 0.59
C-RP mg/L 9.6 (7.1) 12.0 (7.2) 0.30
Note: Values are given as means and (sD).
Abbreviations: FFM, fat-free mass; FM, fat mass; FFMI, fat free mass index; Ree, resting energy expenditure; Ree_hB, resting energy expenditure as a percentage of harris-
Benedict prediction equation; PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension; thb, total hemoglobin; P50, oxygen half saturation tension; PaO2x, oxygen 
extraction tension; C-RP, C-reactive protein.International Journal of COPD 2010:5 35
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EAAs Group no. 13
y = 0.67 × −1.58: r2: 0.68, P < 0.0005
EAAs Group no. 13
y = 0.30 × −0.59: r2: 0.46, P < 0.01
EAAs Group no. 13
y = 0.04 × −1.89: r2: 0.04, P = n.s
EAAs Group no. 13
y = −0.70 × +23.1: r2: 0.46, P < 0.001
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Figure 2 Panel A: 12th-week change FFM, as assessed by DeXA, plotted against 12th-week insulin plasma levels, µUI/mL. Panel B: 12th-week change FFM, plotted against 
12th-week C-RP, mg/L. Panel C: 12th-week change FFM, plotted against 12th-week PaO2x, mmhg in 13 patients allocated to eAAs group. Panel D: 12th-week change FFM, 
plotted against 12th-week glucose plasma levels, mmol/L.
Abbreviations: C-RP, C-reactive protein; DeXA, dual X-ray absorptiometry eAAs, essential amino acid supplementation; FFM, fat-free mass; PaO2x, oxygen extraction tension.
Table 4 Correlations between insulin, C-RP, and PaO2x in eAAs and C groups
Baseline measurements
Group   Insulin C-RP PaO2x Group
e Insulin 0.12 (0.73) −0.39 (0.22) C
A C-RP 0.03 (0.92) 0.56 (0.08) O
A PaO2x −0.34 (0.27) −0.31 (0.32) n
s T
12th-week measurements
e Insulin 0.77 (0.005) −0.87 (0.0005) C
A C-RP 0.71 (0.01) −0.89 (0.0001) O
A PaO2x −0.80 (0.001) −0.79 (0.005) n
s         T 
Note: Values are correlation coefficients and P values given in parentheses.
Abbreviations: C-RP, C-reactive protein; PaO2x, oxygen extraction tension; eAAs, essential amino acid supplementation.International Journal of COPD 2010:5 36
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and C-RP blood levels allows some speculation on the 
involvement of C-RP synthesis pathway in the scenario of 
downregulation of insulin actions by the amino acid mixture 
on signaling to glucose metabolism. Third, the mutual rela-
tionship between tissue oxygen availability, insulin plasma 
levels, and C-RP sheds light on the interaction between tissue 
hypoxia, energy metabolism, and substrate utilization after 
rehabilitation interventions.
The anabolic effect on FFM after nutritional rehabilitation 
is consistent with previous metabolic studies on ingestion 
of proteins, or infusion of mixed amino acids conducted 
in normal human subjects,18,19 and normal-weight COPD 
patients.20 While increased availability of supplemented 
amino acids or increased cellular level of ATP resulting from 
their metabolism is supposed to account for this anabolic 
effect, the notion that branched chain amino acids specifically 
induce protein synthesis suggests a direct action on signaling 
to several metabolic pathways.
Several studies have consistently documented lower 
plasma concentration of branched chain amino acids and 
reduction in glutamate status in COPD patients compared 
to control subjects.5,7,8,21,22 These differences have been 
C Group no. 13
y = 0.01 × +0.062: r2: 0.0003, P = n.s
C Group no. 13
y = 0.06 × −0.49: r2: 0.10, P = n.s
C Group no. 13
y = 0.07 × +0.39: r2: 0.004, P = n.s
C Group no. 13
y = 0.08 × +2.70: r2: 0.06, P = n.s
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Figure 3 Panel A: 12th-week change FFM, as assessed by DeXA, plotted against 12th-week insulin plasma levels, µUI/mL. Panel B: 12th-week change FFM, plotted against 
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specifically associated with weight loss and decreased muscle 
mass, and respectively with reduced muscle glutathione 
levels, and enhanced glycolysis during ischemic and hypoxic 
conditions.8,23 To date however, any cross-talk between amino 
acid and insulin signals as determinant of the switch to FFM 
accretion remains largely speculative in depleted patients 
with COPD.
Reportedly, high physiologic concentrations of branched-
chain amino acids, particularly leucine, activate intermediates 
important in the initiation of protein synthesis, including p70 
S6 kinase and PHAS-I, in synergy with insulin. Concurrently, 
amino acids inhibit early steps of insulin action critical for 
glucose transport and inhibition of gluconeogenesis, includ-
ing decreased insulin-stimulated tyrosine phosphorylation 
of IRS-1 and IRS-2, and a marked inhibition of insulin-
stimulated phosphatidylinositol 3-kinase.9 The significant 
relationship between 12th-week FFM change and 12th-week 
insulin plasma levels in this study extends this hypothesis 
to COPD patients, and provides us with a clinical model to 
explore the amino acid accretion into proteins in relation to 
insulin signaling pathways. The clinical rehabilitation set-
ting of the study prevents the ability of using sophisticated 
techniques to ascertain to which extent glucose uptake 
mechanisms (ie, membrane transport and phosphorylation), 
and their metabolic regulation may contribute to the amino 
acid anabolic effect. Nevertheless, the finding that change 
in FFM bears a strong relationship to insulin plasma levels, 
and no relationship to glucose plasma levels, further sup-
ports the hypothesis of a direct association between insulin 
and amino acid accretion into proteins. These results seem 
to be in line with experimental evidence obtained in the 
ovine fetus that insulin promotes amino acid utilization and 
oxidation, independent of its simultaneous effects on glucose 
metabolism.24
At first, we were puzzled by the observation that higher 
FFM gain was associated with higher C-RP blood levels; 
however, the notion that branched chain amino acids down-
regulate insulin actions on glucose metabolism in vivo, 
specifically blunting glycogen synthesis as well as stimulat-
ing gluconeogenesis, provides us with a line of reasoning to 
explain our findings. The association between CRP and IL-6 
release induced by exercising muscle is well established.25,26 
Furthermore, several lines of evidence raise the intriguing 
possibility that muscle-derived IL-6 has a hormone-like glu-
coregulatory role, signaling critical low levels of glycogen 
content,27 and stimulating hepatic glucose output. Looking 
at the correlation between 12th-week C-RP and 12th-week 
changes in FFM reported in Figure 2B, one may speculate 
that increased C-RP blood levels in patients showing higher 
gain of FFM is a marker of IL-6 overproduction in response 
to impaired insulin action on signaling to glycogen synthesis 
induced by amino acid supplementation. Alternatively, 
C-RP may directly contribute to impairment of insulin 
signaling pathways that promote glucose transport and 
glycogen synthesis,28 while stimulating endogenous glucose 
production.29 Along this line of reasoning, wasting of lean 
body mass, commonly present in patients with COPD, must 
be regarded as a complex process involving changes in the 
control of glucose, as well as of intermediary metabolism 
that is modulated by nutritional signaling through a variety 
of different pathways. Among these, hypoxia seems to play 
a pivotal role in the regulation of metabolic demand of lean 
body mass.8,23 The mutual association between insulin plasma 
levels, C-RP, and PaO2x suggests an interplay between tissue 
oxygen availability and sensing and signaling mechanisms 
to substrate utilization after nutritional rehabilitation.
Limitations of the study
While measuring the change of FFM by DEXA, a well 
validated technique for evaluation of body composition,30,31 
we would rather with this study unravel pathophysiological 
mechanisms elicited by EAAs under condition of wasting 
than specifically address the issue of response to nutritional 
supplementation in COPD. Nevertheless, the prospective 
changes of body weight and FFM we obtained are far 
beyond the reported within-day variability of whole body 
weight.32 In comparison to pretrial information provided 
by randomized controlled trials about the improvements of 
anthropometric measurements by any caloric supplementa-
tion lasting 2 weeks33 this result is clinically meaningful. 
However, there are some limitations to this study.
First, it must be stressed that the number of patients 
allocated to each group was too low to rely on for definitive 
conclusions about the potential benefit of EAAs. Thus, our 
preliminary results should be interpreted with caution, as the 
small number of patients studied may have emphasized the 
positive effect of treatment on body weight and FFM. Second, 
the assessor was not blinded to patient allocation, which 
could have led to bias in evaluating the effect of treatment. 
The higher number of females in the C group although not 
statistically significant likely represents a randomization bias. 
Third, it was apparent that about 14% of the participants had 
some difficulties in adhering to the home-based nutrition-
rehabilitation intervention. Thus, support, motivation, and a 
realistic request for commitment should to be considered for 
future recruitment. Last, although the inability to weigh the International Journal of COPD 2010:5 38
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role of EAAs independent of standardized metabolic load 
of training may be viewed as a confounding factor in the 
evaluation of potential benefits of the study, it was unethical 
to withhold pulmonary rehabilitation in patients who had 
been proved to benefit of this treatment option.
In summary, the potential for supplemented circulating 
amino acids in the regulation of insulin mediated signaling 
to protein and glucose metabolism reconciles the bedside 
with bench investigations. These results provide us with a 
rationale for use of EAAs as a valuable adjunct to exercise 
training programs aimed at stabilizing or even reversing 
the negative effects of lean body mass wasting in COPD 
patients.
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